IP Library Granted Patent US 7,462,471
Granted Patent B2
US 7,462,471 · App. 10/775,768 · Granted Dec 9, 2008

Porous biodegradable polymeric materials for cell transplantation

Assignees: Massachusetts Institute of Technology; Children's Medical Center Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,462,471
App. No.
10/775,768
Granted
Dec 9, 2008
Kind
B2
Abstract

Polymeric materials are used to make a pliable, non-toxic, injectable porous template for vascular ingrowth. The pore size, usually between approximately 100 and 300 microns, allows vascular and connective tissue ingrowth throughout approximately 10 to 90% of the matrix following implantation, and the injection of cells uniformly throughout the implanted matrix without damage to the cells or patient. The introduced cells attach to the connective tissue within the matrix and are fed by the blood vessels. The preferred material for forming the matrix or support structure is a biocompatible synthetic polymer which degrades in a controlled manner by hydrolysis into harmless metabolites, for example, polyglycolic acid, polylactic acid, polyorthoester, polyanhydride, or copolymers thereof. The rate of tissue ingrowth increases as the porosity and/or the pore size of the implanted devices increases. The time required for the tissue to fill the device depends on the polymer crystallinity and is less for amorphous polymers versus semicrystalline polymers. The vascularity of the advancing tissue is consistent with time and independent of the biomaterial composition and morphology.

Claims (2)

1. A polymeric matrix formed of a biodegradable, biocompatible, synthetic, amorphous polymer or semi-crystalline polymer with a degree of crystallinity in the range of from 0 to 24.5% having a porosity of between 45 to 93% and a pore size range of greater than zero to 500 microns that is suitable for attachment and proliferation of dissociated cells, wherein said polymeric matrix further comprises cells selected from the group consisting of hepatocytes, pancreatic islet cells, fibroblasts, chondrocytes, osteoblasts, exocrine cells, cells of intestinal origin, bile duct cells, parathyroid cells, thyroid cells, cells of the adrenal-hypothalamic-pituitary axis, heart muscle cells, kidney epithelial cells, kidney tubular cells, kidney basement membrane cells, nerve cells, blood vessel cells, cells forming bone and cartilage, smooth muscle cells, and skeletal muscle cells.

2. The matrix of claim 1 , further comprising a material enhancing cell attachment to the polymer, wherein said material overlays the polymer.

Assignments (3)
NEGATIVE PLEDGE AGREEMENT Recorded Oct 18, 2012
From: INVIVO THERAPEUTICS HOLDINGS CORP.
To: MASSACHUSETTS DEVELOPMENT FINANCE AGENCY
Reel/Frame 029151/0269 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2008
From: VACANTI, JOSEPH P.
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 021836/0018 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2008
From: GRIFFITH, LINDA G.; SARAKINOS, GEORGIOS; MIKOS, ANTONIOS G.; LANGER, ROBERT S.
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 021836/0478 →
Continuity (4)
Continuation 0966976000 · Sep 26, 2000
Continuation 0805238700 · Apr 23, 1993
Continuation In Part 0801227000 · Feb 1, 1993
Related Publication 20060141000A1 · Jun 29, 2006